title: New Gram Positive Agents to Treat Acute Bacterial Skin and Skin Structure Infections.
abstract: The FDA guidance published in 2013 provided requirements for conducting ABSSSI trials. In 2014, dalbavancin, oritavancin, and tedizolid were introduced into the market after phase III noninferiority clinical trials against vancomycin (for the lipoglycopeptides) and linezolid (for tedizolid), demonstrating clinical efficacy for the treatment of ABSSSI. Great interest exists for these agents because of the postulated financial impact. Due to favorable pharmacokinetics which allow for less frequent medication administration and shorter treatment durations, these agents may prove to reduce hospital admissions and length of stay.
authors.forename: Rosanna
authors.initials: R
authors.lastname: Li
authors.forename: Michael D
authors.initials: MD
authors.lastname: Nailor
mesh_terms: D000900:Anti-Bacterial Agents / Q000191:economics / Q000494:pharmacology; D017326:Clinical Trials, Phase III as Topic; D003365:Costs and Cost Analysis; D006020:Glycopeptides / Q000191:economics / Q000494:pharmacology*; D006801:Humans; D000077427:Lipoglycopeptides; D010755:Organophosphates / Q000191:economics / Q000494:pharmacology*; D010080:Oxazoles / Q000191:economics / Q000494:pharmacology*; D017410:Practice Guidelines as Topic; D017192:Skin Diseases, Bacterial / Q000188:drug therapy*; D017334:Teicoplanin / Q000031:analogs & derivatives* / Q000191:economics / Q000494:pharmacology; D016896:Treatment Outcome; D014640:Vancomycin / Q000031:analogs & derivatives
chemical_list: D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D010755:Organophosphates; D010080:Oxazoles; D017334:Teicoplanin; C469289:dalbavancin; C515040:tedizolid phosphate; C100708:oritavancin; D014640:Vancomycin